Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2026)

Top biotech stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Pharming Group Nv (NASDAQ:PHAR) is the #1 top biotech stock out of 605 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Pharming Group Nv (NASDAQ:PHAR) is: Value: B, Growth: B, Momentum: B, Sentiment: B, Safety: C, Financials: B, and AI: C.

Pharming Group Nv (NASDAQ:PHAR) has a Due Diligence Score of 30, which is 5 points higher than the biotech industry average of 25.

PHAR passed 9 out of 33 due diligence checks and has average fundamentals. Pharming Group Nv has seen its stock return 91.37% over the past year, overperforming other biotech stocks by 123 percentage points.

Pharming Group Nv has an average 1 year price target of $39.00, an upside of 143.6% from Pharming Group Nv's current stock price of $16.01.

Pharming Group Nv stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Pharming Group Nv, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Innoviva (NASDAQ:INVA) is the #2 top biotech stock out of 605 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Innoviva (NASDAQ:INVA) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Innoviva (NASDAQ:INVA) has a Due Diligence Score of 56, which is 31 points higher than the biotech industry average of 25.

INVA passed 17 out of 33 due diligence checks and has strong fundamentals. Innoviva has seen its stock return 26.37% over the past year, overperforming other biotech stocks by 58 percentage points.

Innoviva has an average 1 year price target of $32.25, an upside of 40.77% from Innoviva's current stock price of $22.91.

Innoviva stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Innoviva, 50% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 25% have issued a Strong Sell.

Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #3 top biotech stock out of 605 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: C, Momentum: B, Sentiment: A, Safety: C, Financials: B, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 55, which is 30 points higher than the biotech industry average of 25.

AUPH passed 18 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 73.88% over the past year, overperforming other biotech stocks by 106 percentage points.

Aurinia Pharmaceuticals has an average 1 year price target of $17.33, an upside of 23.98% from Aurinia Pharmaceuticals's current stock price of $13.98.

Aurinia Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Aurinia Pharmaceuticals, 33.33% have issued a Strong Buy rating, 0% have issued a Buy, 66.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 7 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Novabay Pharmaceuticals (NYSEMKT:NBY) has an annual dividend yield of 296.3%, which is 255 percentage points higher than the biotech industry average of 41.74%.

Novabay Pharmaceuticals's dividend payout ratio of -105.3% indicates that its high dividend yield might not be sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 23.37%, which is -18 percentage points lower than the biotech industry average of 41.74%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

Oramed Pharmaceuticals (NASDAQ:ORMP) has an annual dividend yield of 7.62%, which is -34 percentage points lower than the biotech industry average of 41.74%.

Oramed Pharmaceuticals's dividend payout ratio of 16.3% indicates that its high dividend yield is sustainable for the long-term.

Biotech stocks were down -0.09% in the last day, and down -0.75% over the last week. Viridian Therapeutics was the among the top losers in the biotechnology industry, dropping -32.35% yesterday.

Viridian Therapeutics shares are trading lower after the company announced results from its elegrobart REVEAL-1 phase 3 clinical trial in patients with active thyroid eye disease. Elegrobart was generally well tolerated in both dose groups with low rates of hearing impairment.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 56 points higher than the biotech industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -18.95% in the past year. It has overperformed other stocks in the biotech industry by 13 percentage points.

Incyte (NASDAQ:INCY) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Incyte has a valuation score of 86, which is 71 points higher than the biotech industry average of 15. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has gained 49.18% in the past year. It has overperformed other stocks in the biotech industry by 81 percentage points.

Rigel Pharmaceuticals (NASDAQ:RIGL) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Rigel Pharmaceuticals has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Rigel Pharmaceuticals's stock has gained 42.97% in the past year. It has overperformed other stocks in the biotech industry by 75 percentage points.

63.18% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 73.45% over the next year.

2.61% of biotech stocks have a Zen Rating of A (Strong Buy), 4.36% of biotech stocks are rated B (Buy), 48.58% are rated C (Hold), 33.77% are rated D (Sell), and 10.68% are rated F (Strong Sell).